Skip to main content
. 2021 Jul 16;296:114242. doi: 10.1016/j.jviromet.2021.114242

Table 2.

Known SARS-CoV-2 negative (N = 26) and positive (N = 111) samples tested with the developed assay for validation purposes.

Sample panel Mutation determination method No. of samples Variant Fluorescence channel
FAM HEX Texas Red Cy5
Human Negative N/A 20 N/A
Positive (A) Obtained in September 2020, before the emergence of the targeting mutations 20 WT + +
ViroBOAR Spike 1.0 RT-PCR Kit (SARS-CoV-2) & Roche LightCycler 480 II instrument 4 WT + +
21 Alpha (B.1.177) + +
1 Beta (B.1.351) + +
Positive (B) NGS (Illumina MiSeq) 16 WT (B.1.177) + +
2 WT (B.1.258) + +
29 Alpha (B.1.1.7) + +
12 Beta (B.1.351) + +
1 Other (B.1.1.318) + +
Veterinary Negative N/A 3 cats, 3 minks N/A
Positive NGS (Ion Torrent GeneStudio S5) 2 cats WT (B.1.1) + +
NGS (Illumina MiSeq) 3 minks WT (B.1.1.305) + +

N/A: not applicable; WT: wild type; NGS: next-generation sequencing.